[Is routine bone scanning justified during the after-care for breast cancer?].
In a retrospective study of 254 women with carcinoma of the breast (mean age 55.4 years) the occurrence of bone pain was compared with results of skeletal scanning, skeletal X-ray examinations and routine biochemical findings. Typical signs of skeletal metastases were found in bone scans of 119 patients, 88 (74%) of whom had bone pain. Alkaline phosphatase was elevated in 54 (45%), LDH in 32 (27%), and gamma-GT in 69 patients (58%). There was a statistical correlation between the number of affected skeletal parts and the absolute level of alkaline phosphatase (P less than 0.001) and of LDH (P less than 0.05). Skeletal scans gave no evidence of bone metastases in 36 patients who had bone pains. In this group of patients alkaline phosphatase was elevated in 4, LDH in 1 and gamma-GT in 12 patients. Routine scanning of 254 patients revealed skeletal metastases in 12% without any clinical symptoms. Bone pain and (or) increased activity of alkaline phosphatase occurred in 91% of patients with skeletal metastases. In our view, bone scan in the postoperative control of breast cancer is justified only after onset of clinical symptoms and (or) if there is an abnormally raised alkaline phosphatase activity.
D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000378:metabolism; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D001943:Breast Neoplasms / Q000601:surgery*; D004796:Clinical Enzyme Tests; D004164:Diphosphonates; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008875:Middle Aged; D010146:Pain / Q000175:diagnosis; D011877:Radionuclide Imaging; D012189:Retrospective Studies; D013667:Technetium; D013669:Technetium Tc 99m Medronate; D005723:gamma-Glutamyltransferase / Q000378:metabolism
D004164:Diphosphonates; D013667:Technetium; D007770:L-Lactate Dehydrogenase; D005723:gamma-Glutamyltransferase; D000469:Alkaline Phosphatase; D013669:Technetium Tc 99m Medronate
Ist die routinemässige Skelettszintigraphie in der Nachsorge des Mammakarzinoms gerechtfertigt?